Loading...
•
Jun 30, 2023
Bridgebio Q2 2023 Earnings Report
Reported second quarter financial results with key program updates.
Key Takeaways
BridgeBio Pharma reported positive Phase 3 ATTRibute-CM study results for acoramidis and plans to file an NDA with the FDA by the end of 2023. They ended the quarter with $353 million in cash, cash equivalents, marketable securities, and short-term restricted cash, providing runway into 2H 2024.
Announced positive results from the Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM patients, with a highly statistically significant result on the primary endpoint.
Presented updated six-month results from Cohort 5 of PROPEL2, a Phase 2 trial of infigratinib in children with achondroplasia.
Dosed the first participant in FORTIFY, a global Phase 3 study of BBP-418 in patients with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
Three lead KRAS programs are advancing, with an Investigational New Drug (IND) application planned for first-in-class direct KRASG12C (ON) inhibitor BBO-8520 in 2023.
Revenue by Segment
Forward Guidance
BridgeBio anticipates $300-$350 million of investment will support acoramidis from here through the first 12 months of commercial launch.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...